Connected profiles1
Exact peptide identities attached to retained registry observations carrying this condition label.
Official registry condition
End-stage Renal Disease peptide trials
1 selected ClinicalTrials.gov records carrying the official condition label End-stage Renal Disease. The label is copied from each retained registry version and does not imply that PeptideScanner has verified a diagnosis, treatment relationship, or study result.
Registry records
1 selected records.
Connected peptides
1 profiles.
Registry update years
2013–2013 in selected records.
Indication intelligence
Selected evidence landscape
Trial phases1
Phase labels copied from the retained ClinicalTrials.gov versions.
Phase 4 (1)
Registry statuses1
Overall statuses at each retained observation, not necessarily current today.
Completed (1)
Across the connected peptide profiles, PeptideScanner also carries 54 selected PubMed records and 13 selected Drugs@FDA applications. Those records are profile context only; PeptideScanner does not claim they concern End-stage Renal Disease unless their own cited source says so.
Collection change ledger
Recently changed records on this condition hub
These events come only from the exact registry records shown on this page. The condition label does not establish a diagnosis, treatment relationship, or scientific agreement.
Record added
ClinicalTrials.gov record NCT01394341
PeptideScanner retained ClinicalTrials.gov record NCT01394341 at 2026-07-30T21:55:56.622Z. Its registry update date was 2013-10-09, and PeptideScanner's reviewed identity mapping was liraglutide.
- PeptideScanner change date
- August 13, 2026
- Cited source date
- October 9, 2013
- Evidence lane
- Clinical trials
Attributed registry records
Selected records
Liraglutide · 2013-10-09
ClinicalTrials.gov record NCT01394341
Completed at the retained observation.
Open attributed record →